A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Prior treatment

• Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit
• Is taking or has ever taken an interleukin (IL)-17A/IL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study

Lab values

• Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor \[TNF\] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)

Other

• Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score
• Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema.
• Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP

• At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)
• Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit
• Have PPPASI ≥12 at the Screening Visit and Baseline Visit
• Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit
• Have pustules on the palms of the hands and/or soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity ≥2 and having more than 5 active pustules
• Participant must be a candidate for systemic therapy or phototherapy